A daily digest of practical AI agent workflows for non-developers. We isolate actionable no-code guides from viral hype. Scored against human-defined standards.
Daily Summary
4 curated | 4 evaluatedThe no-code agent landscape saw major developments across infrastructure and real-world deployment, from Anthropic's acquisition of a that used Claude to develop experimental treatments, to discussions about and emerging capabilities like . The day highlighted a shift from building agents smarter to making them more capable through better architecture and financial autonomy.
holy f*ck, most people are building Grok Bot teams from scratch. meanwhile, hundreds of ready-made setups are already sitting on GitHub for free. we're talking full AI teams with specialist roles, bots that delegate work to each other, independent verifiers that catch mistakes, and even multi-agent trading desks. and almost nobody is talking about this. that's the gap. 20 GitHub projects worth opening first: 01. grok-skills → 195 reusable playbooks for code review, debugging, research, planning, and shipping. a proven process instead of another vague instruction https://t.co/5U5w1tyx1s 02. botteams → pick a company team and copy its installer prompt. it creates named bots, a group chat, and routines for your approval https://t.co/TnuFCfMCKA 03. grok-bot-templates → 49 templates, 10 teams, 47 skills, and 8 routines. each one defines the role, deliverable, and first task https://t.co/VhNAdb5Lfe 04. hypergrok-trading-desk → 7 specialist bots and 17 skills for research, strategy testing, risk, and execution. trades need your approval https://t.co/EEzYRffcdv 05. awesome-grokbot → a searchable index of public Grok Bot configs organized by job. find a setup that already works for your use case https://t.co/kd7FiRvEgi 06. grok-bot-profiles → Spec Writer, Bug Reproducer, PR Producer, and a separate PR Verifier, so the builder never approves its own work https://t.co/qfgP688XAZ 07. root-agent-skill-framework → a coordinator that sizes the team to your request, creates specialists, and delegates to team leads https://t.co/bLTZMQ0mvZ 08. grok-research → an equity research team with persistent researchers, scout reports, and a shared research database https://t.co/juNqAbLh2V 09. rosterroom → 82 paste-ready team setups for founders, ops, security, finance, and research, each with roles and approval limits https://t.co/YLC6ScWgCw 10. grokbot-for-gtm → an outbound workflow connecting prospect research, email, LinkedIn, replies, and meetings. you approve the sends https://t.co/ftdN5ef3P0 11. grok-bot-token-saver → a chief-and-workers setup that swaps long old threads for compact role cards and clean handoffs https://t.co/5O0YdLk444 12. gojiberryai-sales-os → 13 sales roles covering buying signals, research, copy, follow-ups, and pipeline analysis https://t.co/UL46XCD5vR 13. crew-contract → a working agreement for agent teams: clear missions, named owners, evidence in handoffs, and a budget stop rule https://t.co/9WZEOEx9sb 14. awesome-grokbot by mergisi → paste START.md into a setup bot and pick an engineering, sales, marketing, or ops team https://t.co/XCnfzaYVSM 15. botskills → paste-ready BOT.md setups with required integrations and a clear line on what each bot must never do without you https://t.co/eK49NbmcXg 16. grok-bot-cli → create bots and groups, send messages, and inspect threads from scripts, no manual token copying https://t.co/HWaELohRSV 17. grok-bot-skill → let a coding agent list, message, and create Grok Bot teammates that are already running your workflows https://t.co/eLdldQkZZw 18. awesome-grok-bot by majiayu000 → another searchable catalog of public bot shares, team recipes, and setup guides https://t.co/xQBbi4ce68 19. akeru-bot → a self-hosted alternative with named teammates, per-bot tools, and memory on infrastructure you control https://t.co/Wii0ZQ4tzr 20. guaca → a desktop workspace where agents share conversations, delegate tasks, and use MCP tools. run it locally or on your server https://t.co/rjPP5meb89 how to get value from this: 1. pick one job you already understand 2. find a repo that matches it 3. connect only the tools it needs 4. test the first result before scheduling the code is free. running it still costs your plan, API usage, or hosting. the real advantage isn't 20 bots. it's specialists that check each other's work and know when to stop. the full course below shows how to put the workflow together ↓
🧬 Anthropic just acquired a one-person biotech startup that used Claude to develop an experimental treatment for muscular dystrophy in less than 18 months. And that's only part of the story. Anthropic has revealed that Claude is now being used across real pharmaceutical research programs, from designing antibodies and engineering cancer therapies to organizing experiments, preparing regulatory submissions, and planning clinical trials. The company is working with six biotechnology and pharmaceutical organizations, including Bristol Myers Squibb, Generate Biomedicines, and BigHat Biosciences. It has also started developing potential medicines itself. Some of the early results are surprisingly impressive. 🔬 1. Mithril Medicine: A pharmaceutical startup run by one person and Claude Anthropic acquired Mithril Medicine, a biotech startup founded by Cody Tranbarger, in July 2026. The unusual part? Mithril had just one full-time employee. Tranbarger used Claude as an AI research and operations assistant to manage work across 11 external laboratories. Claude helped with: ▪️ Coordinating experiments and external research partners ▪️ Managing contracts, logistics, and scientific documentation ▪️ Analyzing experimental results and identifying promising drug candidates ▪️ Reviewing historical research and laboratory communications ▪️ Planning subsequent experiments and evaluating potential development risks In one case, Claude reconstructed the status of a research program from email conversations and 14 months of presentation slides, then drafted handover messages for external laboratories. In another, it combined hundreds of antibody-screening files and evaluated candidate molecules within hours. The result? Mithril advanced a potential treatment for LAMA2-related congenital muscular dystrophy, a severe inherited muscle disease, from an initial idea to promising results in mice in under 18 months. In the preclinical study: ▪️ Treated mice showed approximately 2x greater grip strength and muscle force than untreated mice. ▪️ Survival improved: 1 of 8 treated mice died, compared with 4 of 8 untreated mice during the observation period. ▪️ Researchers confirmed that the experimental antibodies reached the relevant muscle tissues. These are early results from a small animal study, not evidence of effectiveness in humans. Anthropic is continuing Mithril's two original muscular dystrophy research programs and plans to investigate additional rare pediatric diseases. The earliest target for human clinical trials is late 2028, assuming the drug candidates continue to perform well. Anthropic calls this approach "Pipeline-in-a-Person": one scientist using AI to coordinate several drug-development programs while external laboratories perform the physical experiments. 🧪 2. Divergence Labs: 35,000 antibody designs in one month This is one of the most striking examples. Divergence Labs is developing a new approach to treating food allergies. Existing medications such as Xolair neutralize IgE, an antibody involved in allergic reactions, but the researchers want to go further. Their proposed treatment would actively detach IgE from immune cells. That requires a specialized antibody with two functional arms: ▪️ Anchor arm: Binds tightly to IgE. ▪️ Disruptor arm: Helps remove IgE from the immune cell. Claude converted the research objective into an experimental design plan and then performed much of the computational work autonomously. The numbers: ▪️ Approximately 35,000 antibody designs generated ▪️ 22 autonomous work sessions ▪️ Around 2,750 GPU-hours across NVIDIA H100 accelerators ▪️ Roughly one month for the design effort ▪️ Laboratory results obtained within weeks, compared with up to nine months on previous comparable projects Claude used molecular modeling tools to filter the generated candidates before scientists selected promising designs for laboratory testing. And some candidates actually worked in early experiments. ▪️ 3 anchor designs successfully bound to IgE. ▪️ 20 disruptor designs demonstrated the ability to dislodge IgE. ▪️ 3 disruptor designs appeared to outperform Xolair on the specific IgE-displacement measurement. Important: These are experimental molecular components, not a completed drug. The researchers still need to combine the two arms, verify that they function together, and test whether the resulting antibody can safely prevent allergic reactions. 🧫 3. Generate Biomedicines: Improving cancer-fighting immune cells Generate Biomedicines worked with Claude Code to redesign part of CAR-T cell therapy, which engineers immune cells to recognize and attack cancer. The research focused on shortening the signaling domain of the engineered receptor. Why does that matter? A smaller signaling component leaves more room in the genetic construct for additional functions, potentially allowing future CAR-T therapies to recognize multiple tumor targets or survive longer. A six-person research team used Claude to explore new designs. The results: ▪️ One design was approximately 70% shorter than the conventional signaling domain. ▪️ Engineered immune cells produced roughly 10x more receptors in laboratory experiments. ▪️ The cells showed improved tumor-cell killing and remained active longer in the reported tests. The work remains preclinical. The next step is evaluating the designs in more complex models and exploring applications against solid tumors. 🧬 4. BigHat Biosciences: AI-designed antibodies with better properties BigHat connected Claude to its automated laboratory data system, Reccy. The goal was to improve antibody fragments across three important characteristics: ▪️ Binding strength ▪️ Thermal stability ▪️ Resistance to aggregation and clumping Over approximately 10 weeks, researchers and Claude designed and experimentally tested around 1,010 molecular variants. The strongest candidates showed: ▪️ More than 10x tighter binding in the best-performing variants ▪️ Up to 18°C improvement in the temperature at which a cancer-targeting candidate remained in solution ▪️ More than 100x slower aggregation for another candidate But perhaps the most interesting discovery wasn't a molecule. When existing experimental measurements appeared inconsistent, Claude helped researchers revisit the raw data, develop better evaluation metrics, and propose adjustments to the laboratory protocol. That suggests AI might contribute not only to molecular design, but also to improving how scientists measure experimental success. 📄 5. Enveda: Cutting pharmaceutical documentation work by 89% Drug development involves enormous amounts of regulated documentation. Enveda integrated Claude into its manufacturing quality-control workflow. The system reviews production records, compares them with approved procedures, and flags potential inconsistencies for human reviewers. In a test covering 1,061 pages of manufacturing documentation: ▪️ Claude detected all 11 issues previously identified by human reviewers. ▪️ It flagged 7 additional issues the reviewers had missed. ▪️ Human review time fell from over 25 hours to less than 3 hours. ▪️ That's an 89% reduction in review time. Claude also helped draft regulatory documentation. One document's initial draft took approximately 4 hours, compared with an estimated three months of manual preparation. Human experts still review and approve the results, and Claude cannot modify the official regulated records. 🏥 6. Bristol Myers Squibb: AI-assisted clinical trial planning Anthropic is also working with pharmaceutical giant Bristol Myers Squibb. Claude is being used to: ▪️ Analyze proprietary clinical development data ▪️ Evaluate trial designs ▪️ Compare possible development strategies ▪️ Estimate the likelihood of clinical trial success BMS reports that Claude produced an initial analysis from a single prompt that would otherwise have taken days. The partners plan to expand their collaboration in 2027. 🏢 7. The Column Group: Building an AI-native biotech company Venture capital firm The Column Group is establishing Pleiades, a biotech company designed around AI-assisted research from the beginning. Its goal is to allow smaller teams to investigate more potential drug targets and operate more research programs. Anthropic and TCG are developing specialized Claude Skills and agent workflows for scientific evaluation. One early skill uses multiple subagents to investigate: ▪️ Biological mechanisms and drug targets ▪️ Human genetics ▪️ Previous clinical trials ▪️ Scientific literature and patents ▪️ Existing competing treatments The initial target-assessment workflow has been evaluated on 45 target-disease pairs. It's still an early-stage initiative, but it could offer a model for smaller, AI-native pharmaceutical research teams. ⚠️ So, has Claude actually discovered new medicines? Not yet in the sense of delivering an approved treatment. These projects are mostly early-stage or preclinical research. The distinction matters: ▪️ Generating thousands of molecular candidates doesn't mean thousands of successful drugs. ▪️ Promising laboratory measurements don't prove clinical effectiveness. ▪️ Positive mouse results don't establish human safety. ▪️ AI-generated research plans still require expert judgment and experimental validation. Anthropic also reports that Claude sometimes pursued unnecessary experiments or struggled to prioritize the most scientifically valuable next step. Human scientists remain responsible for critical decisions. 💡 The bigger picture This announcement is about much more than using a chatbot to answer biological questions. Claude is increasingly operating inside real scientific workflows, connected to laboratory databases, molecular modeling tools, research documents, and external service providers. And Anthropic is no longer just selling AI tools to biotechnology companies. By acquiring Mithril Medicine, it's directly participating in experimental drug development. The most interesting implication might be the economics. If one scientist can coordinate work across multiple laboratories, evaluate thousands of candidates, and manage several research programs with AI assistance, entirely new types of biotech companies could become viable. Especially for rare diseases that are often too expensive for conventional pharmaceutical development. The question is no longer just whether AI can design a promising molecule. It's whether AI can help researchers turn more scientific ideas into experimentally validated treatments, faster and at lower cost. And Anthropic is now putting that hypothesis to the test. 🔗 Full research report: https://t.co/0zSGGJTJrC #Anthropic #ClaudeAI #DrugDiscovery #Biotechnology #AIResearch
Everyone's trying to make AI agents smarter. My agent went from 6/18 to 13/18 real bug fixes without changing the model. The missing piece wasn't intelligence. https://t.co/v9nqeqNqoB
What if an AI agent could not only perform tasks but also independently pay for everything it needs to get the job done? By integrating x402 into Own1, agents can use their own wallets to pay for computing resources, API access, and other services all settled in USDC. At the same time, you remain in control of payments by setting spending limits and defining which operations are permitted. AI is reaching a new level: it no longer just provides assistance it can now autonomously manage the costs of its own workflows. https://t.co/nkv8jmVbpa Get a 10% DISCOUNT with code DVORNIK10 @OpenXNetwork